SCHEMBL4770931

SCHEMBL4770931

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)NCc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.62
SMN1; SMN2 Q16637 4/20 0.52
NPSR1 Q6W5P4 3/20 0.52
LMNA P02545 3/20 0.50
HPGD P15428 1/20 0.50
AGTR1 P30556 1/20 0.48
ALDH1A1 P00352 3/20 0.47
EPHX2 P34913 3/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
NR1H4 Q96RI1 2/20 0.46
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775207 0.94 GAA (0.69) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4776528 0.92 GAA (0.62) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4777502 0.92 GAA (0.62) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4767980 0.91 GAA (0.61) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4777650 0.90 GAA (0.60) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4773553 0.90 GAA (0.60) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4776481 0.90 GAA (0.60) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4771094 0.90 GAA (0.60) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4773527 0.89 GAA (0.58) GAASMN1; SMN2NPSR1LMNAHPGD
SCHEMBL4773548 0.89 GAA (0.58) GAASMN1; SMN2NPSR1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885SMN1; SMN2 1149/4885NPSR1 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.